Miami-based biopharmaceutical company Veru Inc. has made significant strides in the development of potential treatments for COVID-19, breast cancer, and prostate cancer. The company's product lineup includes the FC2 female condom/internal condom for protection against sexually transmitted infections and unintended pregnancy, as well as the Entadfi capsule for the treatment of urinary tract symptoms. Veru Inc.'s drug candidates in development show promise, including Enobosarm in Phase III clinical trials for metastatic breast cancer and Sabizabulin in Phase 3 clinical trials for treating advanced prostate cancer. In addition, Veru Inc. is developing Sabizabulin as an oral microtubule disruptor which has dual antiviral and anti-inflammatory properties to help severe COVID-19 patients at risk of acute respiratory distress syndrome. The company, formerly The Female Health Company, has been in operation since 1971.